Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Gains Clinical Oncology Program Through Aton Acquisition; Lead Agent In Phase II

This article was originally published in The Pink Sheet Daily

Executive Summary

Aton’s suberoylanilide hydroxamic acid would be Merck’s only oncologic in later-stage clinical trials. The acquisition is the second recent example of how Merck is branching into new therapeutic areas.

You may also be interested in...



Merck Enhances Aura Of Cancer Research With Vertex Aurora Kinase Inhibitor Deal

VX-680 is ready to begin Phase I trials; aurora kinase inhibitor could have applicability in a number of cancer types. Merck will pay $20 mil. up front and as much as $350 mil. in milestones to Vertex.

Merck Enhances Aura Of Cancer Research With Vertex Aurora Kinase Inhibitor Deal

VX-680 is ready to begin Phase I trials; aurora kinase inhibitor could have applicability in a number of cancer types. Merck will pay $20 mil. up front and as much as $350 mil. in milestones to Vertex.

Merck/Lundbeck Gaboxadol NDA Planned For 2007; Merck Gets Fourth Phase III NME

The $270 mil. licensing deal with Lundbeck will help boost Merck's pipeline after two significant late-stage setbacks in 2003. The GABA-A receptor agonist gaboxadol would be Merck's entry into the sleep disorder market.

Related Content

Topics

UsernamePublicRestriction

Register

PS058678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel